| Fennec Pharmaceuticals Inc. (FENC) Q1 2025 Earnings Call Transcript |
Fennec Pharmaceuticals Inc. (NASDAQ:FENC ) Q1 2025 Earnings Conference Call May 13, 2025 8:30 AM ET Company Participants Robert Andrade - Chief Financial Officer Jeff Hackman - Chief Executive Officer and Director Conference Call Participants Chase Knickerbocker - Craig Hallum Sudan Loganathan - Stevens Michael Okunewitch - Maxim Group Raghuram Selvaraju - H.C. Wainwright Operator Good morning, ladies and gentlemen. |
seekingalpha.com |
2025-05-13 16:23:04 |
Czytaj oryginał (ang.) |
| Adherex Technologies Inc. (FENC) Reports Q1 Loss, Tops Revenue Estimates |
Adherex Technologies Inc. (FENC) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to earnings of $0.41 per share a year ago. |
zacks.com |
2025-05-13 12:15:36 |
Czytaj oryginał (ang.) |
| Fennec Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025 |
RESEARCH TRIANGLE PARK, N.C., May 08, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its first quarter 2025 financial results before the opening of the U.S. financial markets on Tuesday, May 13, 2025. Management will host a conference call and webcast that day to discuss the Company's financial and business results. |
globenewswire.com |
2025-05-08 20:17:00 |
Czytaj oryginał (ang.) |
| Wall Street Analysts See an 113.25% Upside in Adherex Technologies (FENC): Can the Stock Really Move This High? |
The average of price targets set by Wall Street analysts indicates a potential upside of 113.3% in Adherex Technologies (FENC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. |
zacks.com |
2025-04-30 14:55:39 |
Czytaj oryginał (ang.) |
| Down -22.15% in 4 Weeks, Here's Why Adherex Technologies (FENC) Looks Ripe for a Turnaround |
The heavy selling pressure might have exhausted for Adherex Technologies (FENC) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal. |
zacks.com |
2025-04-10 14:35:44 |
Czytaj oryginał (ang.) |
| Fennec Pharmaceuticals Inc. (FENC) Q4 2024 Earnings Call Transcript |
Fennec Pharmaceuticals Inc. (NASDAQ:FENC ) Q4 2024 Earnings Conference Call March 10, 2025 8:30 AM ET Company Participants Robert Andrade - CFO Jeff Hackman - CEO and Board Member Conference Call Participants Chase Knickerbocker - Craig-Hallum Raghuram Selvaraju - H.C. Wainwright Felix Ampomah - Stephens Michael Okunewitch - Maxim Group Operator Good morning, ladies and gentlemen, and welcome to Fennec Pharmaceuticals Fourth Quarter and Full Year 2024 Earnings and Corporate Update Conference Call. |
seekingalpha.com |
2025-03-10 12:24:58 |
Czytaj oryginał (ang.) |
| Adherex Technologies Inc. (FENC) Reports Q4 Loss, Misses Revenue Estimates |
Adherex Technologies Inc. (FENC) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of $0.56. This compares to loss of $0.10 per share a year ago. |
zacks.com |
2025-03-10 10:19:13 |
Czytaj oryginał (ang.) |
| Fennec Pharmaceuticals Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update |
~ Achieved Full-Year PEDMARK ® Net Product Sales of $29.6 Million, Up 40% Year-Over-Year, and Generated PEDMARK ® Q4 2024 Net Product Sales of $7.9 Million ~ |
globenewswire.com |
2025-03-10 08:03:00 |
Czytaj oryginał (ang.) |
| Fennec Pharmaceuticals to Report Full Year and Fourth Quarter 2024 Financial Results on March 10, 2025 |
RESEARCH TRIANGLE PARK, N.C., March 06, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its full year and fourth quarter 2024 financial results before the opening of the U.S. financial markets on Monday, March 10, 2025. Management will host a conference call and webcast that day to discuss the Company's financial and business results. |
globenewswire.com |
2025-03-06 18:22:00 |
Czytaj oryginał (ang.) |
| Fennec Pharmaceuticals Announces Commercial Launch of PEDMARQSI® In Germany |
~ PEDMARQSI is the First and Only Approved Therapy in the EU and U.K. for the Prevention of Ototoxicity, or Hearing Loss, Induced by Cisplatin Chemotherapy in Patients 1 month to |
globenewswire.com |
2025-02-07 09:00:00 |
Czytaj oryginał (ang.) |
| Is the Options Market Predicting a Spike in Adherex Technologies (FENC) Stock? |
Investors need to pay close attention to Adherex Technologies (FENC) stock based on the movements in the options market lately. |
zacks.com |
2025-01-24 11:46:14 |
Czytaj oryginał (ang.) |
| Fennec Pharmaceuticals Announces Pedmarqsi® Positive Recommendation by NICE for the Prevention of Cisplatin-Induced Hearing Loss in England and Wales |
~ PEDMARQSI® (anhydrous sodium thiosulfate) is the first and only treatment available within NHS England and Wales for the prevention of cisplatin-induced ototoxicity (hearing loss) in children and young people (1 month-17 years of age) ~ |
globenewswire.com |
2024-12-20 08:16:00 |
Czytaj oryginał (ang.) |
| Fennec Pharmaceuticals Announces Early Partial Repayment of Its Outstanding Convertible Debt Facility with Petrichor Healthcare Capital Management |
~ $13 Million Convertible Debt Repayment from Available Cash ~ ~ Elimination of Approximately $1.5 Million in Annual Interest Expense and Potential Equity Overhang of Approximately 1.6 Million Shares ~ RESEARCH TRIANGLE PARK, N.C., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today announced the early repayment of $13 million of the Company's approximately $32 million outstanding convertible debt facility with Petrichor Healthcare Capital Management (“Petrichor”). |
globenewswire.com |
2024-12-19 08:13:00 |
Czytaj oryginał (ang.) |
| Fennec Pharmaceuticals to Participate in Upcoming Investor Conference |
RESEARCH TRIANGLE PARK, N.C., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will be participating in the virtual H.C. Wainwright @ Home Fireside Chat Series taking place on Monday, December 16, 2024 at 11:00 a.m. ET. |
globenewswire.com |
2024-12-12 09:01:00 |
Czytaj oryginał (ang.) |
| Fennec Pharmaceuticals to Participate in Upcoming Investor Conference |
RESEARCH TRIANGLE PARK, N.C., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will be participating in the 15th Annual Craig-Hallum Alpha Select Conference. The Company's management will be available for one-on-one meetings throughout the event. |
globenewswire.com |
2024-11-13 08:27:00 |
Czytaj oryginał (ang.) |
| Fennec Pharmaceuticals Inc. (FENC) Q3 2024 Earnings Call Transcript |
Fennec Pharmaceuticals Inc. (NASDAQ:FENC ) Q3 2024 Earnings Conference Call November 9, 2024 8:30 AM ET Company Participants Robert Andrade - Chief Financial Officer Jeff Hackman - Chief Executive Officer and Director Conference Call Participants Chase Knickerbocker - Craig-Hallum Raghuram Selvaraju - H.C. Wainwright Operator Good morning, ladies and gentlemen, and welcome to Fennec Pharmaceuticals Third Quarter 2024 Earnings and Corporate Update Conference Call. |
seekingalpha.com |
2024-11-10 00:33:09 |
Czytaj oryginał (ang.) |
| Adherex Technologies Inc. (FENC) Reports Q3 Loss, Misses Revenue Estimates |
Adherex Technologies Inc. (FENC) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to loss of $0.07 per share a year ago. |
zacks.com |
2024-11-07 10:26:10 |
Czytaj oryginał (ang.) |
| Fennec Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update |
~ Achieved Third Quarter 2024 Net Product Sales of $7.0 Million ~ ~ Increasing Momentum and Successful Reimbursement in the Adolescent and Young Adult (AYA) Segment Following Strategic Investments to Drive Awareness of Ototoxicity & Adoption of PEDMARK ~ ~ Strengthened Executive Leadership Team with Chief Medical Officer, Chief Commercial Officer & Chief Strategy Officer Appointments ~ ~ Company Has Approximately $40 Million in Cash, Cash Equivalents, and Investment Securities Expected to Fund Operations Into at Least 2026 ~ ~ Management to Host Conference Call Today at 8:30 a.m. ET ~ RESEARCH TRIANGLE PARK, N.C. |
globenewswire.com |
2024-11-07 08:13:00 |
Czytaj oryginał (ang.) |
| Fennec Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 7, 2024 |
RESEARCH TRIANGLE PARK, N.C., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its third quarter 2024 financial results before the opening of the U.S. financial markets on Thursday, November 7, 2024. Management will host a conference call and webcast that day to discuss the Company's financial and business results. |
globenewswire.com |
2024-10-31 08:23:00 |
Czytaj oryginał (ang.) |
| Analysts Estimate Adherex Technologies Inc. (FENC) to Report a Decline in Earnings: What to Look Out for |
Adherex Technologies (FENC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2024-10-28 13:05:38 |
Czytaj oryginał (ang.) |
| Fennec Pharmaceuticals Strengthens Executive Leadership Team with Three Key Appointments to Accelerate the Company's Next Stage of Growth |
~ Pierre S. Sayad, PhD, M.S. |
globenewswire.com |
2024-10-28 08:23:00 |
Czytaj oryginał (ang.) |
| Fennec Pharmaceuticals to Participate in Upcoming Investor Conferences |
RESEARCH TRIANGLE PARK, N.C., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will be participating in upcoming investor conferences. The management team will also host one-on-one investor meetings at the conferences. |
globenewswire.com |
2024-09-05 10:56:00 |
Czytaj oryginał (ang.) |
| Fennec Pharmaceuticals Inc. (FENC) Q2 2024 Earnings Call Transcript |
Fennec Pharmaceuticals Inc. (NASDAQ:FENC ) Q2 2024 Earnings Conference Call August 13, 2024 8:30 AM ET Company Participants Robert Andrade - CFO Jeffrey Hackman - CEO and Board Member Conference Call Participants Chase Knickerbocker - Craig Hallum Naureen Quibria - Capital One Securities Raghuram Selvaraju - H.C. Wainwright Operator Good morning, ladies and gentlemen, and welcome to Fennec Pharmaceuticals Second Quarter 2024 Earnings and Corporate Update Conference Call. |
seekingalpha.com |
2024-08-13 18:20:29 |
Czytaj oryginał (ang.) |
| Adherex Technologies Inc. (FENC) Reports Q2 Loss, Lags Revenue Estimates |
Adherex Technologies Inc. (FENC) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of $0.06. This compares to loss of $0.21 per share a year ago. |
zacks.com |
2024-08-13 12:26:33 |
Czytaj oryginał (ang.) |
| Fennec Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update |
~ Achieved Second Quarter 2024 Total Net Revenues of $7.3 Million ~ ~ Appointed Jeffrey S. Hackman as Chief Executive Officer (CEO) and Member of the Board of Directors ~ ~ Company Has Approximately $43 Million in Cash, Cash Equivalents, and Investment Securities ~ ~ Management to Host Conference Call Today at 8:30 a.m. |
globenewswire.com |
2024-08-13 10:05:00 |
Czytaj oryginał (ang.) |
| Fennec Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 13, 2024 |
Company to Also Participate in 2024 Wedbush PacGrow Healthcare Conference Company to Also Participate in 2024 Wedbush PacGrow Healthcare Conference |
globenewswire.com |
2024-08-06 20:31:00 |
Czytaj oryginał (ang.) |
| Fennec Pharmaceuticals Appoints Jeffrey S. Hackman as Chief Executive Officer and Director |
~ Accomplished Industry Leader Brings Extensive Commercialization and Oncology Expertise ~ ~ Assumes Leadership Role at Critical Time to Expand Use of PEDMARK®, the First and Only Approved Treatment to Reduce the Risk of Cisplatin-Induced Ototoxicity ~ RESEARCH TRIANGLE PARK, N.C., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced the appointment of Mr. |
globenewswire.com |
2024-08-05 10:26:00 |
Czytaj oryginał (ang.) |
| 3 Dirt-Cheap Stocks Under $10 That Could EXPLODE! |
Investing in dirt cheap stocks under $10 has a lot of appeal. One of the benefits is that a low share price allows you to buy more shares with a smaller amount of money. |
investorplace.com |
2024-07-29 10:15:00 |
Czytaj oryginał (ang.) |
| Fennec Pharmaceuticals Announces Management Change |
RESEARCH TRIANGLE PARK, N.C., July 01, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that Adrian Haigh has departed from his position as Fennec's Chief Operating Officer as of June 30, 2024. After nine years as an independent director, in August 2023, Adrian joined the Fennec leadership team as Chief Operating Officer. |
globenewswire.com |
2024-07-01 10:00:00 |
Czytaj oryginał (ang.) |
| Fennec Announces Results of Annual Meeting |
RESEARCH TRIANGLE PARK, N.C., June 25, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (the “Company”) (NASDAQ:FENC) (TSX:FRX) today announced that the nominees listed in the management proxy circular dated April 29, 2024 (the “Circular”) for the Annual General Meeting of Shareholders were elected as directors of the Company at the Annual General Meeting of Shareholders held in New York, New York on June 25, 2024. |
globenewswire.com |
2024-06-25 20:35:00 |
Czytaj oryginał (ang.) |
| Fennec Pharmaceuticals Inc. (FENC) Q1 2024 Earnings Call Transcript |
Fennec Pharmaceuticals Inc. (NASDAQ:FENC ) Q1 2024 Earnings Conference Call May 14, 2024 8:30 AM ET Company Participants Rosty Raykov - Chief Executive Officer and Director Robert Andrade - Chief Financial Officer Adrian Haigh - Chief Operating Officer Conference Call Participants Charles Duncan - Cantor Fitzgerald Chase Knickerbocker - Craig Hallum Michael Okunewitch - Maxim Group Raghuram Selvaraju - HC Wainwright Operator Good morning, ladies and gentlemen. And welcome to the Fennec Pharmaceuticals' First Quarter 2024 Earnings and Corporate Update Conference Call. |
seekingalpha.com |
2024-05-14 17:15:23 |
Czytaj oryginał (ang.) |